Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge

Table 1

Analysis of general information of the patients.

	Total	Group 1	Group 2	Group 3
Patients ()	66	13	9	44
Age group (y)	66	13	9	44
≥50	56	11	8	37	1.000	1.000
<50	10	2	1	7
Time from transplant to cancer groups (y)	61	13	8	40
≥5	33	7	5	21	0.897	1.000
<5	28	6	3	19
Transplants	66	13	9	44
Kidney	42	9	6	27	0.190	0.776
Liver	18	3	1	14
Heart	4	1	1	2
Other^1	2	0	1	1
Tumor type	66	13	9	44
Melanoma	40	13	8	19	0.057	0.409
SCC	6	0	1	5
HCC	10	0	0	10
Other^2	10	0	0	10
Antirejection	65	13	9	43
Glu+CNIs+AP	10	2	2	6	0.886	0.722
Glu+CNIs	17	2	4	11
CNIs	12	1	1	10
CNIs+AP	8	4	1	3
mTOR inhibitor	3	1	0	2
mTOR inhibitor+AP	3	1	0	2
mTOR inhibitor+Glu+AP	2	0	1	1
Glu+AP	3	1	0	2
Glu	2	1	0	1
mTOR inhibitor+Glu	3	0	0	3
Other^3	2	0	0	2

Glu: glucocorticoids; CNIs: calcineurin inhibitors; AP: antiproliferative drugs; SCC: skin squamous cell carcinoma; HCC: hepatocellular carcinoma; other¹: cornea, heart, and kidney; other²: NSCLC, Merkel cell carcinoma, epidermoid carcinoma, and metastatic adenocarcinoma of the duodenum; other³: antilymphocyte antibody+glucocorticoids+calcineurin inhibitors+antiproliferative drugs; y: year. : group 2 compared with group 3; : group 2 compared with group 1.